Rahul N Chavan1, Mark A Cappel2, Rhett P Ketterling3, David A Wada4, Nicole M Rochet5, Ryan Knudson6, Lawrence E Gibson7. 1. Department of Dermatology, Mayo Clinic, Rochester, Minnesota. 2. Department of Dermatology, Mayo Clinic, Jacksonville, Florida. 3. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; Department of Medical Genetics, Mayo Clinic, Rochester, Minnesota. 4. Department of Dermatology, University of Utah, and Huntsman Cancer Institute, Salt Lake City, Utah. 5. College of Medicine, Mayo Clinic, Rochester, Minnesota. 6. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota. 7. Department of Dermatology, Mayo Clinic, Rochester, Minnesota; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota. Electronic address: gibson.lawrence@mayo.edu.
Abstract
BACKGROUND: In patients with malignancy-associated Sweet syndrome, a thorough evaluation for leukemia cutis should be considered. OBJECTIVE: We sought to describe the clinicopathologic characteristics of histiocytoid Sweet syndrome. METHODS: We retrospectively identified patients with histiocytoid Sweet syndrome at our institution from January 1992 through December 2010. We evaluated the underlying cutaneous infiltrate using immunohistochemistry and fluorescence in situ hybridization. RESULTS: We re-evaluated all 22 patients with hematologic malignancy-associated Sweet syndrome. Six patients had a monocytoid infiltrate that was consistent with histiocytoid Sweet syndrome; subsequent evaluation of these patients demonstrated cytogenetic abnormalities on prior bone-marrow biopsy specimens. Fluorescence in situ hybridization analysis was feasible in cutaneous specimens from 5 of the 6 patients and demonstrated the same cytogenetic abnormalities that were identified on prior bone-marrow biopsy specimens in 4 patients. Therefore, these 4 patients may have had a form of leukemia cutis. LIMITATIONS: This was a retrospective study. CONCLUSION: For patients with histiocytoid Sweet syndrome, an underlying hematologic malignancy, and a monocytoid infiltrate on biopsy specimen, fluorescence in situ hybridization of the cutaneous infiltrate may be beneficial to identify cytogenetic abnormalities that may indicate leukemia cutis.
BACKGROUND: In patients with malignancy-associated Sweet syndrome, a thorough evaluation for leukemia cutis should be considered. OBJECTIVE: We sought to describe the clinicopathologic characteristics of histiocytoid Sweet syndrome. METHODS: We retrospectively identified patients with histiocytoid Sweet syndrome at our institution from January 1992 through December 2010. We evaluated the underlying cutaneous infiltrate using immunohistochemistry and fluorescence in situ hybridization. RESULTS: We re-evaluated all 22 patients with hematologic malignancy-associated Sweet syndrome. Six patients had a monocytoid infiltrate that was consistent with histiocytoid Sweet syndrome; subsequent evaluation of these patients demonstrated cytogenetic abnormalities on prior bone-marrow biopsy specimens. Fluorescence in situ hybridization analysis was feasible in cutaneous specimens from 5 of the 6 patients and demonstrated the same cytogenetic abnormalities that were identified on prior bone-marrow biopsy specimens in 4 patients. Therefore, these 4 patients may have had a form of leukemia cutis. LIMITATIONS: This was a retrospective study. CONCLUSION: For patients with histiocytoid Sweet syndrome, an underlying hematologic malignancy, and a monocytoid infiltrate on biopsy specimen, fluorescence in situ hybridization of the cutaneous infiltrate may be beneficial to identify cytogenetic abnormalities that may indicate leukemia cutis.
Authors: A Osio; M Battistella; J-P Feugeas; W Cuccuini; M-E Noguera; T Petrella; E Raffoux; A Janin; Vignon Pennamen Journal: J Invest Dermatol Date: 2015-05-10 Impact factor: 8.551
Authors: Victoria Alegría-Landa; Socorro María Rodríguez-Pinilla; Angel Santos-Briz; José Luis Rodríguez-Peralto; Victor Alegre; Lorenzo Cerroni; Heinz Kutzner; Luis Requena Journal: JAMA Dermatol Date: 2017-07-01 Impact factor: 10.282
Authors: Grégoire Martin de Frémont; Pierre Hirsch; Santiago Gimenez de Mestral; Philippe Moguelet; Yoan Ditchi; Jean-François Emile; Patricia Senet; Sophie Georgin-Lavialle; Thomas Hanslik; François Maurier; Amir Adedjouma; Noémie Abisror; Thibault Mahevas; Florent Malard; Lionel Adès; Pierre Fenaux; Olivier Fain; François Chasset; Arsène Mekinian Journal: Front Immunol Date: 2021-10-04 Impact factor: 7.561
Authors: Seung Dohn Yeom; Hye Soo Ko; Jong Hyuk Moon; Min Ji Kang; Ji Won Byun; Gwang Seong Choi; Jeonghyun Shin Journal: Ann Dermatol Date: 2017-08-25 Impact factor: 1.444